Engineered immune cells take aim at childhood cancer
NCT ID NCT00085930
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new treatment for children with high-risk neuroblastoma, a type of cancer. Researchers took the patients' own immune cells (T cells) and modified them to recognize and attack the cancer. Some of these cells were also trained to fight a common virus (EBV) to help them last longer in the body. The main goal was to see if this treatment was safe and to learn how long the cells survived.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Texas Children's Hospital
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioated molecule shrink untreatable neuroblastoma?
- Slowing down immunotherapy infusion may reduce pain in children with Tough-to-Treat neuroblastoma
- Targeted radiation zaps childhood brain tumors in early trial
- Triple-Attack CAR-T cells take aim at stubborn neuroblastoma
- New Antibody-Drug conjugate targets Hard-to-Treat cancers
- Donor 'Memory' immune cells take on childhood cancer